-
EP4205763
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP Citations: EP4205763
| Cited in | Search | Type: | Patent literature | Publication No.: | CN111388686
[XY] (BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL et al.) [X] 1 * paragraph [0010] *[Y] 2 | Type: | Patent literature | Publication No.: | WO2019025440
[A] (BAYER PHARMA AG et al.) [A] 1,2 * page 47, lines 21-25 * | Type: | Non-patent literature | Publication information: | [XY] MASTERSON LIAM ET AL: "Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?", INTERNATIONAL JOURNAL OF CANCER, vol. 146, no. 8, 28 January 2020 (2020-01-28), US, pages 2305 - 2314, XP093187007, ISSN: 0020-7136, Retrieved from the Internet | DOI: | http://dx.doi.org/10.1002/ijc.32869 | Type: | Non-patent literature | Publication information: | [XY] CHIUN HSU ET AL: "Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study [FULL TEXT HTML]", JOURNAL OF CLINICAL ONCOLOGY VOLUME 35, NUMBER 36, 24 August 2017 (2017-08-24), pages 1 - 15, XP093187051, Retrieved from the Internet | Type: | Non-patent literature | Publication information: | [A] ZHANG LI ET AL: "Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes", MOLECULAR CANCER RESEARCH, vol. 15, no. 12, 30 November 2017 (2017-11-30), US, pages 1722 - 1732, XP093187016, ISSN: 1541-7786, Retrieved from the Internet |